ArticleNature biomedical engineering2019
A microfluidic assay for the quantification of the metastatic propensity of breast cancer specimens.
Article in Nature biomedical engineering, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 82 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
82 citing papers in PubMed.
- Plasma-Activated Medium Suppresses Lung Cancer H1299 Cell Migration through the MAPK Pathway.Cell biochemistry and biophysics · 2026Article
- HyPIC-3D enables characterization of migratory cancer cell subpopulations in 3D hypoxic microenvironments.Cell reports methods · 2026Article
- TBXA2R activates ERMs to drive motility, invasion, and metastatic colonization of TNBC cells.Life science alliance · 2026Article
- Delivery of Pleckstrin-Homology Domains Suppresses PI3K/Akt Signaling and Breast Cancer Metastasis.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Article
- Common Signatures of Altered Gene Regulation and Invasiveness of Different Breast Cancer Cell Lines after Matrix Interface Crossing.Advanced healthcare materials · 2026Article
- Cell-nanoplastics association impacts cell proliferation and motility.bioRxiv : the preprint server for biology · 2026Article
- Article
- Methods to analyze cell migration data: fundamentals and practical guidelines.Nature methods · 2026Review
- 3D bioprinting innovations: a new frontier in breast cancer research.Medical oncology (Northwood, London, England) · 2025Review
- The Rise of Mechanobiology for Advanced Cell Engineering and Manufacturing.Advanced materials (Deerfield Beach, Fla.) · 2025Review
- Cytoplasmic anillin and Ect2 promote RhoA/myosin II-dependent confined migration and invasion.Nature materials · 2025Article
- Enhanced Unidirectional Cell Migration Induced by Asymmetrical Micropatterns with Nanostructures.Journal of functional biomaterials · 2025Article
- 3D-printed plugs enhance cell usage efficiency for single-cell migration and neuron axon guidance assays.Cell reports methods · 2025Article
- Phenotypic plasticity and secretory heterogeneity in subpopulations derived from single cancer cell.Acta pharmaceutica Sinica. B · 2025Article
- Adhesion strength of tumor cells predicts metastatic disease in vivo.Cell reports · 2025Article
- Advances in microfluidic platforms for tumor cell phenotyping: from bench to bedside.Lab on a chip · 2025Review
- Frontiers in mechanobiology and mechanomedicine.Med-X · 2025Article
- Cytoskeletal activation of NHE1 regulates mechanosensitive cell volume adaptation and proliferation.Cell reports · 2024Article
- Impact of Nanomedicine in Women's Metastatic Breast Cancer.Small (Weinheim an der Bergstrasse, Germany) · 2024Review
22 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
- Erratum issued
Authors and funding
14 authors.
Funding
Abstract
The challenge of predicting which patients with breast cancer will develop metastases leads to the overtreatment of patients with benign disease and to the inadequate treatment of aggressive cancers. Here, we report the development and testing of a microfluidic assay that quantifies the abundance and proliferative index of migratory cells in breast cancer specimens, for the assessment of their metastatic propensity and for the rapid screening of potential antimetastatic therapeutics. On the basis of the key roles of cell motility and proliferation in cancer metastasis, the device accurately predicts the metastatic potential of breast cancer cell lines and of patient-derived xenografts. Compared with unsorted cancer cells, highly motile cells isolated by the device exhibited similar tumourigenic potential but markedly increased metastatic propensity in vivo. RNA sequencing of the highly motile cells revealed an enrichment of motility-related and survival-related genes. The approach might be developed into a companion assay for the prediction of metastasis in patients and for the selection of effective therapeutic regimens.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.